Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca will voluntarily withdraw the listing of its American Depositary Shares and certain US dollar-denominated debt securities from Nasdaq as it completes a direct listing of its ordinary shares and all US debt securities on the New York Stock Exchange after market close on 30 January 2026. The move forms part of a shareholder-approved plan to harmonise the company’s share listing structure, creating a unified global platform that allows investors to trade AstraZeneca’s ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE under the unchanged ticker AZN, and is intended to simplify access for global investors and support the company’s positioning as a globally traded biopharmaceutical leader.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £110.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic expansions and product approvals further enhance its outlook. However, the high valuation and moderate technical indicators slightly temper the overall score.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focused on the discovery, development and commercialisation of prescription medicines across Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide, positioning the group as a major player in the global pharmaceutical industry.
Average Trading Volume: 2,180,081
Technical Sentiment Signal: Strong Buy
Current Market Cap: £217.9B
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.